These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 36327699)

  • 1. Hopes on immunotherapy targeting B7-H3 in neuroblastoma.
    Pulido R; Nunes-Xavier CE
    Transl Oncol; 2023 Jan; 27():101580. PubMed ID: 36327699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B7-H3 in Brain Malignancies: Immunology and Immunotherapy.
    Guo X; Chang M; Wang Y; Xing B; Ma W
    Int J Biol Sci; 2023; 19(12):3762-3780. PubMed ID: 37564196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. B7-H3 in Pediatric Tumors: Far beyond Neuroblastoma.
    Bottino C; Vitale C; Dondero A; Castriconi R
    Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting B7-H3-A Novel Strategy for the Design of Anticancer Agents for Extracranial Pediatric Solid Tumors Treatment.
    Rasic P; Jeremic M; Jeremic R; Dusanovic Pjevic M; Rasic M; Djuricic SM; Milickovic M; Vukadin M; Mijovic T; Savic D
    Molecules; 2023 Apr; 28(8):. PubMed ID: 37110590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CAR T cells redirected to B7-H3 for pediatric solid tumors: Current status and future perspectives.
    Epperly R; Gottschalk S; DeRenzo C
    EJC Paediatr Oncol; 2024 Jun; 3():. PubMed ID: 38957786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy.
    Zhao B; Li H; Xia Y; Wang Y; Wang Y; Shi Y; Xing H; Qu T; Wang Y; Ma W
    J Hematol Oncol; 2022 Oct; 15(1):153. PubMed ID: 36284349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. B7-H3 immunoregulatory roles in cancer.
    Mortezaee K
    Biomed Pharmacother; 2023 Jul; 163():114890. PubMed ID: 37196544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel anti-B7-H3 chimeric antigen receptor from a single-chain antibody library for immunotherapy of solid cancers.
    Birley K; Leboreiro-Babe C; Rota EM; Buschhaus M; Gavriil A; Vitali A; Alonso-Ferrero M; Hopwood L; Parienti L; Ferry G; Flutter B; Himoudi N; Chester K; Anderson J
    Mol Ther Oncolytics; 2022 Sep; 26():429-443. PubMed ID: 36159778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. B7-H3-targeted CAR-T cell therapy for solid tumors.
    Li G; Wang H; Wu H; Chen J
    Int Rev Immunol; 2022; 41(6):625-637. PubMed ID: 35855615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The miR-29 family facilitates the activation of NK-cell immune responses by targeting the B7-H3 immune checkpoint in neuroblastoma.
    Pathania AS; Chava H; Chaturvedi NK; Chava S; Byrareddy SN; Coulter DW; Challagundla KB
    Cell Death Dis; 2024 Jun; 15(6):428. PubMed ID: 38890285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiparametric flow cytometry highlights B7-H3 as a novel diagnostic/therapeutic target in GD2neg/low neuroblastoma variants.
    Dondero A; Morini M; Cangelosi D; Mazzocco K; Serra M; Spaggiari GM; Rotta G; Tondo A; Locatelli F; Castellano A; Scuderi F; Sementa AR; Eva A; Conte M; Garaventa A; Bottino C; Castriconi R
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33795387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B7-H3, a checkpoint molecule, as a target for cancer immunotherapy.
    Yang S; Wei W; Zhao Q
    Int J Biol Sci; 2020; 16(11):1767-1773. PubMed ID: 32398947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in immunotherapeutic targets for childhood cancers: A focus on glypican-2 and B7-H3.
    Li N; Spetz MR; Li D; Ho M
    Pharmacol Ther; 2021 Jul; 223():107892. PubMed ID: 33992682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune checkpoint B7-H3 is a therapeutic vulnerability in prostate cancer harboring PTEN and TP53 deficiencies.
    Shi W; Wang Y; Zhao Y; Kim JJ; Li H; Meng C; Chen F; Zhang J; Mak DH; Van V; Leo J; St Croix B; Aparicio A; Zhao D
    Sci Transl Med; 2023 May; 15(695):eadf6724. PubMed ID: 37163614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy.
    Picarda E; Ohaegbulam KC; Zang X
    Clin Cancer Res; 2016 Jul; 22(14):3425-3431. PubMed ID: 27208063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B7-H3 Expression in Breast Cancer and Brain Metastasis.
    Joshi V; Beecher K; Lim M; Stacey A; Feng Y; Jat PS; Duijf PHG; Simpson PT; Lakhani SR; McCart Reed AE
    Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. To kill a cancer: Targeting the immune inhibitory checkpoint molecule, B7-H3.
    Kanchan RK; Doss D; Khan P; Nasser MW; Mahapatra S
    Biochim Biophys Acta Rev Cancer; 2022 Sep; 1877(5):188783. PubMed ID: 36028149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B7-H3/CD276: An Emerging Cancer Immunotherapy.
    Zhou WT; Jin WL
    Front Immunol; 2021; 12():701006. PubMed ID: 34349762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting B7-H3 Immune Checkpoint With Chimeric Antigen Receptor-Engineered Natural Killer Cells Exhibits Potent Cytotoxicity Against Non-Small Cell Lung Cancer.
    Yang S; Cao B; Zhou G; Zhu L; Wang L; Zhang L; Kwok HF; Zhang Z; Zhao Q
    Front Pharmacol; 2020; 11():1089. PubMed ID: 32848731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New Emerging Targets in Cancer Immunotherapy: The Role of B7-H3.
    Koumprentziotis IA; Theocharopoulos C; Foteinou D; Angeli E; Anastasopoulou A; Gogas H; Ziogas DC
    Vaccines (Basel); 2024 Jan; 12(1):. PubMed ID: 38250867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.